Tenecteplase drug bests standard treatment for certain strokes

March 22, 2012 By Serena Gordon, HealthDay Reporter in Cardiology

New drug bests standard treatment for certain strokes

Tenecteplase seems as safe as the usual clot-busting drug, study says.

(HealthDay) -- A medication called tenecteplase may be more effective at treating strokes caused by clots in large blood vessels in the brain than the current standard therapy, Australian researchers report.

"This study compares a newer thrombolytic medicine [tenecteplase] to the standard thrombolytic medicine [alteplase] in the treatment of patients with acute ," explained study author Dr. Mark Parsons, an associate professor at the University of Newcastle School of Medicine and Public Health and a senior staff specialist in neurology at John Hunter Hospital, in Newcastle.

Thrombolytic drugs are essentially clot-busters. The researchers found that tenecteplase was better at restoring blood flow to the after a stroke than alteplase. In addition, fewer people treated with a higher dose of tenecteplase had a serious disability at 90 days after their stroke compared to those on alteplase.

Results of the study are published in the March 22 issue of the . Funding for the study came from the Australian National Health and Medical Research Council.

Acute ischemic strokes occur when a clot blocks blood supply to the brain. Both tenecteplase and alteplase are from a class of medications known as a (tPA). When given within three hours of the first , intravenous tPA can open up the blocked blood vessel in the brain and prevent further brain damage.

Recovery after receiving one of these medications can be fast and dramatic, though this isn't always the case. And, excessive bleeding is a significant risk factor associated with these medications.

The current study included 75 people treated within six hours after an . All received advanced computed tomography (CT) imaging to ensure that there wasn't any stroke-induced brain damage yet, and the researchers also looked for people who were having strokes in a large blood vessel.

Parsons said the researchers used the advanced CT screening to "identify stroke patients with the greatest potential to benefit from thrombolytic treatment."

The patients were randomly assigned to receive either a standard dose of alteplase, or one of two different doses of tenecteplase (0.1 milligrams (mg) per kilogram (kg) of body weight or 0.25 mg per kg). A kilogram is about 2.2 pounds. All received the medication less than six hours after the onset of symptoms, according to the study.

Blood flow of both tenecteplase groups was restored more effectively than for the alteplase patients. People in the tenecteplase groups also showed greater clinical improvements than those on alteplase after 24 hours.

The higher dose of tenecteplase appeared to be more effective. After 90 days, 72 percent of those treated with the higher dose of tenecteplase were free of serious disability compared to just 40 percent of those on alteplase.

There were no significant differences in excessive bleeding in the brain or other serious adverse events, according to the study.

"The perfect clot-busting drug would open up the blockage without causing any hemorrhage. Short of that, the goal is to find a drug that works at least as well, if not better, and that's as safe," said Dr. Keith Siller, director of the Comprehensive Stroke Center at NYU Langone Medical Center in New York City.

"They showed that under ideal circumstances, this drug works well. It still remains to be seen if other types of strokes will be helped as much," said Siller.

Hemorrhagic strokes, which occur when a blood vessel in the brain bursts, are less common than ischemic strokes.

Parsons said he and his colleagues hope to broaden the study population in their next study. They said the current findings warrant moving on to a study comparing the drugs' performance within a shorter window for treatment.

Siller said that while researchers are trying to refine the type of clot-busting drug that might work best, the message to the public remains clear: If you have any symptoms of , get to the hospital as soon as possible.

"All of these treatments require patients to come to the hospital as soon as possible," noted Siller, who added that treatments currently need to be administered within three hours after the onset of symptoms.

More information: Learn the warning signs of stroke from the National Stroke Association.

Copyright © 2012 HealthDay. All rights reserved.

4.5 /5 (2 votes)  

Rank 4.5 /5 (2 votes)
Relevant PhysicsForums posts

More news stories

New blood-thinner measures may cut medication errors

Blood thinners are the preferred treatment option to prevent heart attacks, blood clots and stroke, but they are not without risk, and not just because of their side effects. These high-risk drugs, known as anticoagulants, ...

Cardiology created 40 minutes ago | popularity not rated yet | comments 0

Registry questions superiority of bivalirudin over heparin

Results from a large observational study reported at EuroPCR 2013 today question whether bivalirudin is superior to heparin in the absence of GPIIb/IIIa blockade, showing similar 30-day mortality in patients with non-ST segment ...

Cardiology created 43 minutes ago | popularity not rated yet | comments 0

Study shows low rate of late lumen loss with bioresorbable DESolve device

The DESolve bioresorbable coronary scaffold system achieves good efficacy and safety with low rates of late lumen loss and major coronary adverse events at six months, show first results from the pivotal DESolve Nx trial ...

Cardiology created 44 minutes ago | popularity not rated yet | comments 0

Biodegradable stent proves non-inferior to drug-eluting stent

The Orsiro stent, which is a novel stent platform eluting sirolimus from a biodegradable polymer, demonstrated non-inferiority to the Xience Prime everolimus-eluting stent for the primary angiographic endpoint of in-stent ...

Cardiology created 16 hours ago | popularity 5 / 5 (1) | comments 0

Post-approval TAVI registry shows high rates of device success at one year

One-year results from SOURCE XT – one of the largest, post-approval transcatheter aortic valve implantation (TAVI) registries to-date – reported today at EuroPCR 2013 show good clinical outcomes in routine clinical practice, ...

Cardiology created 16 hours ago | popularity not rated yet | comments 0


Addiction to unhealthy foods could help explain the global obesity epidemic

Research presented today shows that high-fructose corn syrup can cause behavioural reactions in rats similar to those produced by drugs of abuse such as cocaine. These results, presented by addiction expert Francesco Leri, ...

Study finds COPD is over-diagnosed among uninsured patients

More than 40 percent of patients being treated for COPD at a federally funded clinic did not have the disease, researchers found after evaluating the patients with spirometry, the diagnostic "gold standard" for chronic obstructive ...

Small increase in cancer risk following CT scans in childhood and adolescence

Study leader, Professor John Mathews from the University of Melbourne said this small increase in cancer risk must be weighed against the undoubted benefits from CT scans in diagnosing and monitoring disease.

Indian medics reconstruct baby's swollen head

Indian doctors said Wednesday they have successfully carried out a first round of reconstructive surgery on the skull of a baby suffering from a rare disorder that caused her head to nearly double in size.

How healthy are you for your age?

On May 22, JoVE will publish details of a technique to measure the health of human genetic material in relation to a patient's age. The method is demonstrated by the laboratory of Dr. Gil Atzmon at New York's Albert Einste ...

Addiction as a disorder of decision-making

New research shows that craving drugs such as nicotine can be visualized in specific regions of the brain that are implicated in determining the value of actions, in planning actions and in motivation. Dr. Alain Dagher, from ...